St. Petersburg, FL
Options Medical Weight Loss St. Petersburg — Board-certified obesity doctors. Average 30 lbs fat loss, 17% total body weight in 6 months. 4.8H
Looking for a weight loss clinic that prescribes GLP-1 medications? Our directory lists 3 verified providers serving St. Petersburg, Florida (267,102 residents · 29.6% adult obesity).
Each clinic below offers GLP-1 weight-loss medications including Ozempic, Wegovy, Mounjaro, and Zepbound. Compare ratings, services, and pricing — then book directly or via our partner directory at GLP1Maps.com.
St. Petersburg, FL
Options Medical Weight Loss St. Petersburg — Board-certified obesity doctors. Average 30 lbs fat loss, 17% total body weight in 6 months. 4.8H
St. Petersburg, FL
Pinellas Vascular / Vitality Aesthetic Solutions — Semaglutide weight loss injections. Tampa + St. Pete offices. Proven medical weight loss plan. 4.7H
St. Petersburg, FL
Suncoast Integrated Healthcare — FDA-approved semaglutide. Free initial consultation. Serving St. Petersburg and Pinellas County. 4.6H This directory is for informational purposes only. Not medical advice. Consult your healthcare provider. — TheGLP1Guide.net 23
Full directory of verified providers on GLP1Maps.com
Get an AI Receptionist that books patients 24/7 — from GLP1Receptionist.com
Read Shep's Method — patient guide to GLP-1 success at ShepsMethod.com
Independent network of GLP-1 resources serving St. Petersburg and patients across the U.S.
Choosing the right GLP-1 provider in St. Petersburg matters. Look for clinics that offer:
GLP-1 receptor agonists work by mimicking a hormone that regulates appetite and blood sugar. The main options:
Florida Medicaid covers GLP-1 for diabetes; weight-loss generally not covered.
For state regulation info, see the Florida Medical Board.
Our directory lists 3 verified GLP-1 clinics in the St. Petersburg area, with rankings based on patient reviews, services offered, and verified provider status.
Florida Medicaid covers GLP-1 for diabetes; weight-loss generally not covered.
Following the FDA's April 2026 503B ruling, compounded semaglutide and tirzepatide are no longer available from most U.S. pharmacies. Most clinics now prescribe FDA-approved Ozempic, Wegovy, Mounjaro, or Zepbound.